Source:http://linkedlifedata.com/resource/pubmed/id/14961579
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2004-2-12
|
pubmed:abstractText |
Generation of immune responses against B cell chronic lymphocytic leukemia (B-CLL) has been the aim of several studies that have demonstrated a poor antigen presenting ability of B-CLL cells and an inconsistent emergence of T cells capable of killing efficiently the leukemic cells. CD1d is a restriction element structurally related to the major histocompatibility complex (MHC) and capable of presenting lipid antigens to CD1d-restricted T cells (also defined as natural killer-T [NKT] cells). The synthetic lipid alpha-galactosylceramide (alpha-GalCer) has been characterized as a potent stimulator of CD1d-restricted T cells. We have investigated the expression of CD1d on B-CLL cells. CD1d was detected by flow cytometric analyses on leukemic cells of all B-CLL cases studied (n = 38) and was expressed at higher density on cells carrying unmutated immunoglobulin variable region (IgV) genes. In addition, CD1d on B-CLL cells mediated the presentation of alpha-GalCer to CD1d-restricted T cells, which in turn induced B-CLL cell death. At variance with another study (Metelitsa et al., Leukemia 2003;17:1068-77), no correlation between expression levels of CD1d and susceptibility to NKT cell lysis was observed. Proliferation and production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) by CD1d-restricted T cells, in the presence of B-CLL cells loaded with alpha-GalCer, were also observed. Our study demonstrates that B-CLL cells express a monomorphic restriction element that is functionally capable of antigen presentation and can be useful to design novel B-CLL immunotherapies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD1,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Galactosylceramides,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2004 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
109
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
402-11
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:14961579-Antigen Presentation,
pubmed-meshheading:14961579-Antigens, CD1,
pubmed-meshheading:14961579-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:14961579-Cell Division,
pubmed-meshheading:14961579-Cohort Studies,
pubmed-meshheading:14961579-Flow Cytometry,
pubmed-meshheading:14961579-Galactosylceramides,
pubmed-meshheading:14961579-Humans,
pubmed-meshheading:14961579-Immunoglobulin Variable Region,
pubmed-meshheading:14961579-Interferon-gamma,
pubmed-meshheading:14961579-Killer Cells, Natural,
pubmed-meshheading:14961579-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:14961579-T-Lymphocytes,
pubmed-meshheading:14961579-Tumor Necrosis Factor-alpha
|
pubmed:year |
2004
|
pubmed:articleTitle |
CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.
|
pubmed:affiliation |
Human Anatomy Section, Department of Experimental Medicine, University of Genoa, Genova, Italy. franco.fais@unige.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|